3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
46
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
26
Paclitaxel
25
Carboplatin
19
Bevacizumab
13
Specimen Handling
11
Magnetic Resonance Spectroscopy
9
Doxorubicin
8
Cisplatin
8
Taxes
7
Biopsy
7
olaparib
6
lenvatinib
6
Fulvestrant
6
durvalumab
5
dostarlimab
5
Nivolumab
5
Megestrol Acetate
5
Letrozole
5
Gemcitabine
5
Docetaxel
5
trastuzumab deruxtecan
4
Trastuzumab
4
Tirzepatide
4
Progestins
4
Medroxyprogesterone Acetate
4
Fluorouracil
4
palbociclib
3
ipatasertib
3
atezolizumab
3
abemaciclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
enzalutamide
×
90 days
×
Clear all
No trials found.